BRCA1 and ovarian cancer: In the same line, retrospective analysis from the SOLO2 trial, assessing olaparib as maintenance therapy in BRCA1/2 mutant platinum-sensitive relapse ovarian cancers, showed a significantly longer TTST in patients who previously received placebo as compared to patients who received olaparib as maintenance therapy (12.1 months vs. 6.9 months HR = 2.17 [95% CI = 1.47–3.19]) (43).